Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | RRM1 | P23921 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13397198 | 0.93 | NOD1 (0.43) | NOD1RRM1DPP7GNAI3GNAO1 | |
| SCHEMBL13397027 | 0.92 | DPP7 (0.43) | NOD1RRM1DPP7GNAI3GNAO1 | |
| SCHEMBL16124766 | 0.86 | DPP7 (0.55) | GLP1RNOD1RRM1DPP7GNAI3 | |
| SCHEMBL13396480 | 0.83 | RRM1 (0.43) | NOD1RRM1DPP7GNAI3GNAO1 | |
| SCHEMBL5148905 | 0.83 | GRM8 (0.37) | GLP1RNOD1NOS1LTA4HCA2 | |
| SCHEMBL13396454 | 0.82 | DPP7 (0.43) | NOD1RRM1DPP7GNAI3GNAO1 | |
| SCHEMBL13397074 | 0.80 | RRM1 (0.38) | RRM1DPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL13396402 | 0.80 | GNAI3 (0.49) | RRM1DPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL13396385 | 0.79 | NOS1 (0.41) | RRM1DPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL14135391 | 0.79 | GLP1R (0.40) | GLP1RNOD1RRM1DPP7GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266820-B2 | Nitric oxide donor compounds | NICOX SCIENCE IRELAND (IE) | 2016-02-23 | — | — | US | disclosed |
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | GLP1R 1597/4885NOD1 1456/4885RRM1 3946/4885 |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | GLP1R 1946/4885NOD1 1292/4885RRM1 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.